aTyr Pharma (LIFE) has received a new Buy rating, initiated by H.C. Wainwright analyst, Joseph Pantginis.
Joseph Pantginis has given his Buy rating to aTyr Pharma due to a combination of factors. The pharmaceutical company recently initiated its Phase 2 EFZO-CONNECT study on efzofitimod for patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), an endeavor that Pantginis views as favorable. This is because the ongoing progress of the trial not only amplifies aTyr’s clinical development ambitions but also has the potential to increase shareholder value.
Furthermore, Pantginis highlights the potential for expanding efzofitimod’s clinical profile. During a recent meeting with aTyr’s management team, the discussion focused on the progress of its clinical pipeline, with emphasis on efzofitimod. Pantginis sees potential in preclinical data from aTyr that could open up new avenues for future exploration with efzofitimod. Also, a recent finding related to a mutation in the HARS gene linked to Usher Syndrome Type 3B (USH3B) suggests a promising opportunity for efzofitimod in this indication. These factors combined led Pantginis to give aTyr Pharma a Buy rating.
In another report released today, Piper Sandler also maintained a Buy rating on the stock with a $20.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
aTyr Pharma (LIFE) Company Description:
aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Read More on LIFE:
- aTyr Pharma presents efzofitimod data
- aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
- aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- aTyr Pharma reports Q2 EPS (22c), consensus (28c)
